Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by CancerSlayeron Feb 08, 2022 12:34am
511 Views
Post# 34407406

RE:RE:RE:RE:RE:TLT Filling Up With Cash

RE:RE:RE:RE:RE:TLT Filling Up With Cash

Great news today....& fortunately things are calming down on the Pandemic front, which should help with enrollment.  I also agree that 2023 is a realistic timeframe.

I found the following comment in today's NR intriguing...

'Further research by UM also identified that the spike protein responsible for the transmission of a coronavirus into a host cell, remained intact after light-activated TLD-1433 inactivation, suggesting that the vaccine developed by this technology could potentially stimulate a protective antibody immune response in a mammalian host."

The key to an effective inactivated vaccine is the preservation of the primary viral component (the epitope/spike protein in this case) once the virus is inactivated.   It is this primary epitope that can elicit a more effective neutralizing immune response.  Preserving a key epitope during the inactivation process is certainly not a given...as various agents used in this process can often change/destroy the primary epitope.  The fact that the light-activated TLD-1433 was able to preserve the spike protein in full after 99.99% inactivation is a "big deal" imo.  It not only indicates incredible potential as a preventative against multiple virus types, it also opens the door for its potential use as a therapeutic.  Another thought...it is also possible that during the inactivation process, other potential antigens (i.e. damage-associated molecular patterns, etc.) could be unleashed that could serve as a vaccine adjuvant to further boost the immune response...?


Such a versatile compound/tech is bound to bring good news for many years to come...GLTA.

 

<< Previous
Bullboard Posts
Next >>